Results
FISH was confirmatory in 28 cases only (8.48%; 19 cases of 22q11.2 microdeletion, 5 cases of Prader Willi, 3 cases of William and 1 case of TRP syndrome). There were 8 cases with mosaicism and 20 cases with pure deletion. Microarray was picked up copy number variation (CNV) with or without copy neutral loss of heterozygosity (LOH) in approximately 70% of cases, mostly involving several chromosome loci. However, aCGH was failed to pick up mosaic cases (with even 45% deleted cell lines). Clinically suspected specific locus CNV was detectable in approximately 24% cases only by aCGH. Variation in deletion sizes and or break point differences (with genes involvement variations) as well as other CNVs with or without LOH was evident.
Conclusions
We conclude that FISH in this format should not be the method of choice for clinically suspected microdeletion syndromes as cost, labor & time versus benefit is unjust. Microarray seems better technique, in clinically doubtful cases. However, microarray is likely going to miss mosaic cases, if deleted cell lines concentration is less than 50%. It seems time has come to follow strict clinical criteria for FISH testing or preferably to follow better methods viz., DNA microarray (array comparative genomic hybridization). We think that whole genome screening should be adopted as first line of investigation and FISH may be used for detecting mosaicism, screening family members and prenatal diagnosis. Furthermore, microdeletion syndrome best fitted with genomic disorder as several chromosomal loci are involved in CNV with or without LOH and alteration in deletion size or breakpoint. Our study has not found identical deletion profile in any cases, thus
